ERBB2 and metastatic neoplasm: The risk of development of the CNS metastases as the first site of metastatic disease was statistically higher in patients with HER2-positive breast cancer as well as for triple-negative patients (HR 3.66, 95% CI 1.78–7.55, p = 0.0004 and HR 6.50, 95% CI 3.32–12.71, p < 0.0001) compared to patients with luminal A-like breast cancer.